
    
      This study is to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in
      Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately
      Controlled Triglyceride Level by Atorvastatin Monotherapy. After administrating the
      atorvastatin or Pravafenix Cap. (pravastatin sodium/fenofibrate) for 8 weeks, evaluate the
      variation of the Non-HDL-C for each arm. Ultimatly verificaite the Pravafenix Cap.
      (pravastatin sodium/fenofibrate) have better effects than atorvastatin.
    
  